Ceritinib Dosing Guide: 450mg Once Daily with Food – Key Administration Points

　　1.Overview and Core Dosing Information

　　Ceritinib(brand name:Zykadia)is a highly selective second-generation oral anaplastic lymphoma kinase(ALK)tyrosine kinase inhibitor,indicated for patients with advanced ALK-rearranged non-small cell lung cancer(NSCLC).Compared with first-generation ALK inhibitors,ceritinib demonstrates stronger inhibitory activity against multiple ALK resistance mutations,providing a critical therapeutic alternative for patients who have progressed on or are intolerant to crizotinib.

　　The dosing regimen has been optimized through clinical studies.The current recommended adult dose is 450 mg once daily,taken with food.This regimen offers comparable efficacy to the earlier high-dose fasting regimen(750 mg once daily fasting)while significantly improving gastrointestinal tolerability,and has become the globally accepted standard.

　　2.Pharmacokinetic Rationale for Taking with Food

　　Ceritinib's oral absorption is highly dependent on bile secretion and food stimulation.Clinical pharmacokinetic studies show that taking ceritinib with food increases its bioavailability by approximately 58%to 100%,while also reducing inter-individual variability in absorption and producing more predictable plasma concentrations.

　　Specifically,taking the drug with a meal—particularly one containing some fat—promotes bile secretion,enhancing drug dissolution and absorption in the gastrointestinal tract.By contrast,fasting administration results in lower absorption and greater concentration fluctuations,potentially leading to subtherapeutic exposure or excessive peak levels in some patients.Therefore,"take with food"is not an optional suggestion but a necessary condition for achieving effective therapeutic concentrations.Patients should take ceritinib at approximately the same time each day,shortly after starting a meal,to maintain a consistent routine.

　　3.Dose Modification and Adverse Reaction Management

　　Ceritinib dose adjustments must follow a stepwise reduction protocol—patients must never self-increase or self-decrease the dose.When intolerable adverse reactions occur(such as diarrhea,nausea,vomiting,elevated liver enzymes,or interstitial lung disease),the treating physician should reduce the dose based on the severity of the event:

　　First reduction:450 mg once daily→300 mg once daily

　　Second reduction:300 mg once daily→150 mg once daily

　　If the 150 mg once-daily dose remains intolerable,permanent discontinuation should be considered.It is important to emphasize that dose adjustment aims to balance efficacy and safety,rather than simply enduring side effects at the original dose.For grade 3 or higher adverse reactions,treatment should be interrupted promptly and resumed at a reduced dose once the event has resolved to≤grade 1.

　　4.Missed-Dose Protocol

　　Missed doses may occasionally occur during long-term targeted therapy.The following principles apply to ceritinib:

　　If a dose is missed and more than 12 hours remain until the next scheduled dose,take the missed 450 mg dose immediately,then take the next dose at the regular time.

　　If fewer than 12 hours remain​until the next scheduled dose,skip the missed dose and take the next dose at the regular time.

　　Never take a double dose(900 mg)to make up for a missed dose,as this can cause a sudden spike in drug exposure and trigger severe gastrointestinal toxicity or other adverse reactions.

　　5.Important Notes on Overseas Generic Versions

　　Multiple generic versions of ceritinib are available from manufacturers in various regions.While these products share the same active ingredient,differences in formulation,excipients,and dissolution profiles may lead to variations in bioavailability and tolerability.

　　Patients using overseas generic versions should carefully review the specific package insert that accompanies their medication,confirming the recommended dose,administration instructions(whether food is required),and dose modification guidelines.Details may differ between manufacturers,and patients should not simply assume that the original brand(Zykadia)labeling applies to their generic product.It is also advisable to keep the source information and insert on file,and to proactively inform the treating physician of the specific product version at every follow-up visit,enabling accurate dosing and safety decisions.

　　6.Summary

　　The safe and effective use of ceritinib rests on three core principles:450 mg once daily,taken with food,and no self-adjustment of dose.Strict adherence to these principles ensures optimal anti-tumor efficacy while minimizing the risk of adverse reactions.For patients using overseas generic products,verifying the specific product's labeling is an essential additional safeguard against medication errors.